* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download T - Florida Department of Corrections
Survey
Document related concepts
Influenza A virus wikipedia , lookup
2015–16 Zika virus epidemic wikipedia , lookup
Ebola virus disease wikipedia , lookup
Orthohantavirus wikipedia , lookup
Hepatitis B wikipedia , lookup
Herpes simplex virus wikipedia , lookup
West Nile fever wikipedia , lookup
Antiviral drug wikipedia , lookup
Marburg virus disease wikipedia , lookup
Lymphocytic choriomeningitis wikipedia , lookup
Transcript
FLORIDA DEPARTMENT OF CORRECTIONS OFFICE OF HEALTH SERVICES _______________________________________________________________________________ HEALTH SERVICES BULLETIN NO: 15.03.08 Page 1 of 8 SUBJECT: DC POLICY ON HUMAN IMMUNODEFICIENCY VIRUS DISEASE AND CONTINUITY OF CARE EFFECTIVE DATE: 04/01/08 _______________________________________________________________________________ I. PURPOSE: The purpose of this health services bulletin is to provide information and guidelines for testing, diagnosis, and treatment of Human Immunodeficiency Virus for inmates at all correctional facilities and to provide for continuity of medications for Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome patients. II. TESTING: A. Confidential testing for Human Immunodeficiency Virus is to be encouraged to all inmates on a voluntary basis upon intake or during incarceration. Mandatory testing for Human Immunodeficiency Virus is a component of end-of-sentence requirements. No co-payment is to be charged for Human Immunodeficiency Virus testing, pre-test, or post-test counseling. B. Human Immunodeficiency Virus tests can be requested by any inmate. Each institution will be responsible for testing its own permanent-party inmates and those of the community facilities for which the institution is responsible. See attachment “1” Notice to Inmates (English/Spanish) for bulletin board notifications. C. Human Immunodeficiency Virus tests shall be conducted with prior informed consent of the inmate. The inmate shall be informed of the right to confidential treatment concerning the inmate's identity and test results. The inmate shall also be informed prior to testing about prevention of exposure to and transmission of Human Immunodeficiency Virus and shall have a return visit for the purpose of disclosing test results and conducting post-test counseling. If the test result is positive, the counselor must advise the inmate of the availability of mental health counseling and partner notification services by the Department of Health Sexually Transmitted Disease staff (as per the Department of Health Model Protocol for Human Immunodeficiency Virus Test Counseling, see attachment “2”). D. Pre-test and post-test counseling and the inmate's signed consent for Human Immunodeficiency Virus testing will be documented on “Consent for Human Immunodeficiency Virus Testing,” DC4-783 which is to be filed in the health record behind pink divider “Communicable Diseases Record,” DC4-710. _____________________________________________________________________________ HEALTH SERVICES BULLETIN NO: 15.03.08 Page 2 of 8 SUBJECT: DC POLICY ON HUMAN IMMUNODEFICIENCY VIRUS DISEASE AND CONTINUITY OF CARE _____________________________________________________________________________ E. All Human Immunodeficiency Virus test results must be reviewed by a physician or clinical associate. F. No Human Immunodeficiency Virus test result shall be determined as positive or revealed to any person as positive without confirmatory testing. G. Inmates who are negative upon testing may request that another Human Immunodeficiency Virus test be done in six (6) months. Subsequent testing will be based on clinical judgment and justification by the clinician. H. All Human Immunodeficiency Virus positive results will be entered on the “Problem List,” DC4-730. I. All inmates with a positive Human Immunodeficiency Virus result will be referred to the physician/clinical associate for further workup and enrolled into the Immunity Clinic. J. All admissions to reception centers must have documentation of Human Immunodeficiency testing recommendation. This can be accomplished thru documentation of Inmate Reception Orientation. K. When an inmate reports the history of a positive Human Immunodeficiency Virus test, an attempt will be made to obtain a copy of the test result from a previous departmental chart or the previous medical care provider. The inmate must sign a “Consent for Authorization for Use and Disclosure Inspection and Release of Confidential Information,” DC4-711B before the department makes contact with an outside provider. L. All inmates involved in a situation where there has been a significant exchange of body fluids will be tested, except for those who are known to be Human Immunodeficiency Virus positive. Human Immunodeficiency Virus screening will be repeated at six (6) weeks, three (3) months, and six (6) months if the affected inmate remains negative. Inmates who are exposed shall be offered a preventive treatment based on a medical evaluation of the exposure. M. Mandatory Human Immunodeficiency Virus testing is to be performed within one (1) year of end-of-sentence. 1. The senior health services administrator is responsible for taking reasonable steps to ensure that Human Immunodeficiency Virus testing is completed on every inmate within one (1) year of end-of-sentence, and not less than sixty (60) days before the inmate's tentative release date. _____________________________________________________________________________ HEALTH SERVICES BULLETIN NO: 15.03.08 Page 3 of 8 SUBJECT: DC POLICY ON HUMAN IMMUNODEFICIENCY VIRUS DISEASE AND CONTINUITY OF CARE _____________________________________________________________________________ III. 2. Inmates refusing the mandatory end-of-sentence test will be counseled by the nursing supervisor. If the inmate continues to refuse, the inmate's name and circumstance of the refusal will be reported to the senior health services administrator, regional health services office and the assistant secretary of health services. 3. Inmates with positive confirmatory test results are to be reported to the designated medical case manager. Pursuant to section 381.004, Florida Statutes, a written consent is not needed provided there is documentation in the record the test has been explained and that a verbal consent was given. Staff will document on the DC4-783 under the consent section that verbal consent was given and that two (2) staff members witnessed the consent. 4. The senior health services administrator will report each month to the regional health services administrator the total number of end-of-sentence tests performed, the total number with positive and negative test results, the number who refused, the number who received medication, and the number who did not need end-of-sentence testing. CARE PLAN: A. All Human Immunodeficiency Virus positive inmates will be followed in the Immunity Clinic for assessment, clinical evaluation, and monitoring. Periodic examinations, laboratory testing, tuberculosis screening, x-rays, and vaccinations will be provided as outlined in health services bulletin “Chronic Illness Monitoring and Clinic Establishment Guidelines,” 15.03.05. Clinicians are expected to utilize specialty consultation when needed. B. Prophylaxis against opportunistic infections will be provided for all Human Immunodeficiency Virus positive inmate patients as clinically indicated: 1. Pneumocystis carinii pneumonia prophylaxis will be provided for persons with CD4<200 cells/ul (or <14%). Prophylaxis can be discontinued for those responding to treatment with a CD4 level >200 cells/ul sustained more than three (3) months. (Note: Glucose-6-Phosphate Dehydrogenase determination must be normal before commencing Dapsone therapy.) 2. Toxoplasma gondii prophylaxis will be provided for persons with CD4<100 cells/ul. Prophylaxis can be discontinued for those responding to treatment with a CD4 level >200 cells/ul sustained more than three (3) months. _____________________________________________________________________________ HEALTH SERVICES BULLETIN NO: 15.03.08 Page 4 of 8 SUBJECT: DC POLICY ON HUMAN IMMUNODEFICIENCY VIRUS DISEASE AND CONTINUITY OF CARE _____________________________________________________________________________ C. IV. 3. Mycobacterium avium prophylaxis will be provided for persons with CD4<50 cells/ul. Primary prophylaxis can be discontinued for those responding to treatment with a CD4 level> 1 00 cells/ul sustained more than three (3) months. 4. Mycobacterium tuberculosis prophylaxis will be provided for Human Immunodeficiency Virus infected persons with a tuberculin skin test result of 5mm or greater, or those who are close contacts of persons with infectious tuberculosis. Antiretroviral therapy will be considered for Human Immunodeficiency Virus positive inmate patients who: 1. Have a Human Immunodeficiency Virus Ribonucleic Acid (RNA) viral load >100,000 copies/mL and/or CD4 <350 cells/ul 2. Have acute Human Immunodeficiency Virus syndrome or within six (6) months of seroconversion 3. Demonstrate symptoms of Human Immunodeficiency Virus infection 4. Are pregnant D. Patients considered for antiretroviral therapy must commit to medication adherence. All antiretroviral medication is to be single-dose administration with the exception of inmate patients in work release centers or those participating in discharge preparations. Inmate patients who are non-adherent will be reviewed by the clinician and antiretroviral therapy medication may be discontinued. E. Special diets are only indicated with clinical justification. F. Dental service guidelines are provided in “Dental Services/Standard Operating Instructions,” 15.04.13. REPORTING: A. All newly identified Human Immunodeficiency Virus infected inmates and all new cases of Acquired Immunodeficiency Syndrome diagnosed in accordance with CDC standards must be reported to the Department of Health using the "Acquired Immunodeficiency Syndrome Adult Confidential Case Report" form (CDC 50.42A) or Acquired Immunodeficiency Syndrome case report form. A copy of the report form should be filed in the medical record behind “Communicable Diseases Record,” DC4-710 (pink chart divider). Additionally, all newly identified Human Immunodeficiency Virus-infected inmates must be reported to the Department of Corrections Human Immunodeficiency Virus Prerelease Planner for the appropriate Region. _____________________________________________________________________________ HEALTH SERVICES BULLETIN NO: 15.03.08 Page 5 of 8 SUBJECT: DC POLICY ON HUMAN IMMUNODEFICIENCY VIRUS DISEASE AND CONTINUITY OF CARE _____________________________________________________________________________ B. V. Reporting by a local hospital does not replace DC reporting. WORK RELEASE: Inmates who are Human Immunodeficiency Virus infected and on medications may be placed in work release settings. VI. A. When the decision is made to transfer a Human Immunodeficiency Virus infected inmate to a work release center, plans will be made to provide Human Immunodeficiency Virus-related medications. B. Medication related to Human Immunodeficiency Virus disease will be provided on a monthly basis by the major institution that is responsible for the work release center. C. The inmate will continue to be followed at the major institution for Immunity Clinic. DISCHARGE PLANNING: Discharge planning must be done for Human Immunodeficiency Virus infected inmate patients. A. In order to prepare and better educate inmates who have controlled Human Immunodeficiency Virus Infections/ Acquired Immunodeficiency Syndrome to prepare for their own care after release (end-of-sentence), six (6) months prior to end of sentence inmate patients on medications who have demonstrated adherence will be offered the opportunity to keep medications on persons. The clinician should schedule reevaluation in one month after this change to assess adherence. B. Within six (6) months of end-of-sentence, the assigned Human Immunodeficiency Virus prerelease planner will coordinate continuity of care with a community care provider, and/or county health department. The assigned Human Immunodeficiency Virus prerelease planner communicates verbally with the assigned classification officer and provides requested documentation. C. Refer to health services bulletin “Prerelease Planning Continuity of Health Care,” 15.03.29 for guidelines on planning for continuity of care. D. Inmates who receive any medication(s) which is approved by the Department of Health Acquired Immunodeficiency Syndrome Drug Assistance Program will be referred to this program for follow-up care after release from a Department of Corrections facility. _____________________________________________________________________________ HEALTH SERVICES BULLETIN NO: 15.03.08 Page 6 of 8 SUBJECT: DC POLICY ON HUMAN IMMUNODEFICIENCY VIRUS DISEASE AND CONTINUITY OF CARE _____________________________________________________________________________ E. A MAXIMUM THIRTY (30) DAY SUPPL Y OF CURRENTLY PRESCRIBED MEDICATIONS (SUFFICIENT TO PROVIDE THE EXITING INMATE WITH TREATMENT UNTIL TREATMENT IS RECEIVED FROM A NONDEPARTMENT OF CORRECTIONS PROVIDER) WILL ACCOMPANY THE INMATE, ALONG WITH A REFERRAL TO AN APPROPRIATE MEDICAL FACILITY. F. If the inmate is on any Human Immunodeficiency Virus-related medications, the designated medical case manager for Human Immunodeficiency Virus prerelease planning will contact the Department of Health Acquired Immunodeficiency Syndrome Patient Care Office in Tallahassee at 850/413-0674 or SC 293-0674 to establish preliminary eligibility and discharge plans. The Department of Health office will be provided with the information needed to establish eligibility for the Acquired Immunodeficiency Syndrome Drug Assistant Program and the name of the county where the inmate will reside after release and where s/he will obtain health care. G. The medical case manager will establish an appointment for the inmate at the county health department as soon as the end-of-sentence date is known. H. The following information shall be copied from the medical chart and such information shall be transmitted to the appropriate county health department, and/or community care provider where the inmate will receive health care after release: 1. Human Immunodeficiency Virus test result showing a Western Blot confirmation of a positive result. 2. The latest Cluster of Differentiation (CD4) count. 3. The latest Viral load test result. 4. Any information that documents an Acquired Immunodeficiency Syndrome related opportunistic infection (see Infection Control Program Manual for a list). 5. Chart forms or an accurate listing of medication history. 6. A list of current medications related to treatment of Human Immunodeficiency Virus infection. _____________________________________________________________________________ HEALTH SERVICES BULLETIN NO: 15.03.08 Page 7 of 8 SUBJECT: DC POLICY ON HUMAN IMMUNODEFICIENCY VIRUS DISEASE AND CONTINUITY OF CARE _____________________________________________________________________________ VII. EDUCATION: A. Florida statutes mandate education on Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome for Department of Corrections staff and inmates. Education will be provided to inmates at reception, transfer to a permanent institution, and prior to release. Periodic updates will be offered as needed. This education must be provided and documented (see attachment “3” Inmate Reception Orientation: Human Immunodeficiency Virus Infection Education Lesson Plan and Curriculum). B. Annual documentation of training for medical and nonmedical staff is required, and Human Immunodeficiency Virus counselor training is to be provided for staff who perform the pre-test and post-test counseling. In March of each year, Office of Health Services staff will prepare an annual report to the legislature on staff and inmate educational efforts. VIII. RELEVANT FORMS AND DOCUMENTS: A. B. C. D. E. F. G. H. I. J. K. L. DC4-710 Communicable Disease Record DC4-711B Consent for Authorization for Use and Disclosure Inspection and Release of Confidential Information DC4-730 Problem List DC4-783 Consent for Human Immunodeficiency Virus Testing Health Services Bulletin 15.03.05 Chronic Illness Monitoring and Clinic Establishments Guidelines Health Services Bulletin 15.03.29 Prerelease Planning Continuity of Health Care Health Services Bulletin 15.04.13 Dental Services/Standard Operating Instructions CDC 50.42A Department of Health Acquired Immunodeficiency Syndrome Adult Confidential Case Report Infection Control Manual Notice to Inmates (English and Spanish) Attachment “1” Department of Health Model Protocol for Human Immunodeficiency Virus Testing Counseling - Attachment “2” Inmate Reception Orientation: Human Immunodeficiency Virus Infection Education Lesson Plan and Curriculum - Attachment “3” ________________________________________ Assistant Secretary of Health Services _________________________ Date _____________________________________________________________________________ HEALTH SERVICES BULLETIN NO: 15.03.08 Page 8 of 8 SUBJECT: DC POLICY ON HUMAN IMMUNODEFICIENCY VIRUS DISEASE AND CONTINUITY OF CARE _____________________________________________________________________________ This Health Services Bulletin Supersedes: HSOI 87-05 dated 3/27/87 Interoffice Memorandum dated August 7, 1990 Re: DC Policy on Human Immunodeficiency Virus Disease HSAM 97-4 dated 9/12/97 and 5/21/98 HSB 15.03.08 dated 4/1/88, 5/2/88, 12/5/88, 5/26/89, 1/29/92, 11/8/93, 3/31/94, 5/20/96, 3/5/97, 9/11/01, and 06/08/04